Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Phase 3

Active, not recruiting

Conditions: Stage II Non-Small Cell Lung Cancer AJCC v7
Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Stage III Non-Small Cell Lung Cancer AJCC v7
Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Stage IIIB Non-Small Cell Lung Cancer AJCC v7

Interventions: Drug: Carboplatin
Drug: Cisplatin
Biological: Durvalumab
Drug: Etoposide
Drug: Paclitaxel
Drug: Pemetrexed Disodium
Radiation: Photon Beam Radiation Therapy
Radiation: Proton Beam Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2013-11-25

Last Posted Date: 2024-12-18

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 330

Registration Number: NCT01993810

Locations: 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 27 locations

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

Phase 1

Completed

Conditions: Extensive-Stage Small-Cell Lung Cancer

Interventions: Drug: Carfilzomib
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2013-11-19

Last Posted Date: 2017-08-28

Lead Sponsor: Amgen

Target Recruit Count: 32

Registration Number: NCT01987232

Locations: 🇷🇺
State Budgetary Healthcare Institution of Yaroslavl Region "Regional Clinical Oncological Hospital", Yaroslavl, Russian Federation
🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇷🇺
Regional Budgetary Healthcare Institution "Kursk Regional Clinical Oncology Dispensary", Kislino, Kursk, Russian Federation

and more 14 locations

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma

Interventions: Drug: Crizotinib
Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ifosfamide
Drug: Methotrexate

First Posted Date: 2013-11-08

Last Posted Date: 2024-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 137

Registration Number: NCT01979536

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States

and more 151 locations

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Stage I Diffuse Large B-Cell Lymphoma
Stage III Diffuse Large B-Cell Lymphoma
CD20 Positive
Stage IV Diffuse Large B-Cell Lymphoma
Stage II Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Carfilzomib
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Rituximab

First Posted Date: 2013-10-10

Last Posted Date: 2024-08-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 29

Registration Number: NCT01959698

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

Early Phase 1

Completed

Conditions: Childhood Diffuse Large Cell Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma
Contiguous Stage II Small Lymphocytic Lymphoma
Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Childhood Small Noncleaved Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Contiguous Stage II Adult Burkitt Lymphoma

Interventions: Drug: busulfan
Drug: etoposide
Drug: cyclophosphamide
Procedure: peripheral blood stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2013-10-10

Last Posted Date: 2015-08-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 33

Registration Number: NCT01959477

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Lung
Stage IIIA Non-small Cell Lung Cancer
Adenosquamous Cell Lung Cancer
Large Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Bronchoalveolar Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Squamous Cell Lung Cancer

Interventions: Dietary Supplement: soy isoflavones
Drug: cisplatin
Drug: pemetrexed disodium
Drug: etoposide
Radiation: radiation therapy

First Posted Date: 2013-10-09

Last Posted Date: 2020-11-23

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01958372

Locations: 🇺🇸
Karmanos Cancer Institute at McLaren Bay Region, Bay City, Michigan, United States
🇺🇸
Karmanos Cancer Institute at McLaren Central Michigan, Mount Pleasant, Michigan, United States
🇺🇸
Karmanos Cancer Institute at McLaren Lapeer Region, Lapeer, Michigan, United States

and more 2 locations

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Phase 2

Active, not recruiting

Conditions: Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Desmoplastic Small Round Cell Tumor
Ewing Sarcoma of Bone or Soft Tissue
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Interventions: Drug: vincristine
Drug: doxorubicin
Drug: cyclophosphamide
Drug: ifosfamide
Drug: etoposide
Drug: temozolomide
Procedure: surgery
Drug: temsirolimus
Radiation: radiation
Drug: bevacizumab
Drug: sorafenib

First Posted Date: 2013-09-19

Last Posted Date: 2024-10-17

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 24

Registration Number: NCT01946529

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Phase 1

Completed

Conditions: Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

First Posted Date: 2013-08-13

Last Posted Date: 2020-08-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01921387

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2

Active, not recruiting

Conditions: Stage II Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma

Interventions: Drug: brentuximab vedotin
Drug: etoposide
Drug: prednisone
Drug: doxorubicin
Drug: cyclophosphamide
Drug: Dacarbazine(R)
Drug: filgrastim
Other: quality of life assessment
Radiation: radiation therapy

First Posted Date: 2013-08-12

Last Posted Date: 2024-11-21

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 77

Registration Number: NCT01920932

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Maine Children's Cancer Program (MCCP), Scarborough, Maine, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States

and more 3 locations

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: lenalidomide
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine

First Posted Date: 2013-07-22

Last Posted Date: 2018-10-29

Lead Sponsor: Stanford University

Target Recruit Count: 17

Registration Number: NCT01904643

Locations: 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy